-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the State Medical Products Administration conditionally approved the listing of Class 1 innovative drug Linplisset tablets (trade name: Intarui) declared by Shanghai Yingli Pharmaceutical Co.
, Ltd.
through the priority review and approval process
.
The drug is an innovative drug independently developed in China with independent intellectual property rights, and is suitable for adult patients
with relapsed or refractory follicular lymphoma who have received at least two systemic treatments in the past.
, Ltd.
through the priority review and approval process
.
The drug is an innovative drug independently developed in China with independent intellectual property rights, and is suitable for adult patients
with relapsed or refractory follicular lymphoma who have received at least two systemic treatments in the past.
Linplisset is a selective inhibitor
of the δ isoform (PI3Kδ) of phosphatidylinositol-3-kinase.
Linplisset tablets can inhibit the expression of PI3Kδ protein and reduce the phosphorylation level of AKT protein, thereby inducing apoptosis and inhibiting the proliferation
of malignant B cells and primary tumor cells.
The listing of this drug provides a treatment option
for adult patients with relapsed and refractory follicular lymphoma after treatment with existing treatments.
of the δ isoform (PI3Kδ) of phosphatidylinositol-3-kinase.
Linplisset tablets can inhibit the expression of PI3Kδ protein and reduce the phosphorylation level of AKT protein, thereby inducing apoptosis and inhibiting the proliferation
of malignant B cells and primary tumor cells.
The listing of this drug provides a treatment option
for adult patients with relapsed and refractory follicular lymphoma after treatment with existing treatments.
